Journal article · 2026 · Open access
Evidence-based treatment for treatment resistant schizophrenia
European Psychiatry, 69(S1), S51 · Published 1 June 2026 · DOI 10.1192/j.eurpsy.2026.10281
In brief
“Evidence-based treatment for treatment resistant schizophrenia” is a 2026 journal article by Pavel Mohr, published in European Psychiatry. OpenAlex counts 0 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at European Psychiatry.
- Citations
- 0
- Authors
- 1
Abstract
Treatment-resistant schizophrenia (TRS) is a common clinical problem, up to 30% of patients show little or no response to treatment. The most comprehensive definition of TRS was coined by the Treatment Response and Resistance in Psychosis (TRRIP) working group. First step in the management of TRS is to rule out pseudoresistance, i.e., failure to respond from different reasons (non-adherence, poor metabolizers, incorrect diagnosis, comorbidity, insufficient dosage or duration of trial, masking side effects). There is a general agreement among various treatment guidelines, the drug of choice for TRS is clozapine. Recent meta-analyses, systematic reviews, and individual meta-analyses cast doubts on clozapine superiority, suggesting that other antipsychotics (e.g., olanzapine, clozapine) may as effective as clozapine. However, it should be noted that in many RCTs clozapine was underdosed; numerous studies where clozapine arm was not blinded were excluded from analyses, severely resistant patients were not included, and finally, clozapine was significantly superior to comparator drugs when disregarding RCTs sponsored by the manufacturer of the comparator. Patients who do not respond or do not tolerate clozapine (“ultra-resistant schizophrenia”) may benefit from clozapine augmentation. Data indicate that clozapine can be effectively combined with ECT, mirtazapine, or memantine for overall symptoms, with ECT for positive symptoms, memantine, duloxetine, or mirtazapine for negative symptoms. Real-world data from Finnish and Swedish national registers showed that the dose of an augmenting agent is important (standard doses of SSRIs and SNRIs, medium doses of aripiprazole). Non-pharmacological therapeutic options for TRS, in monotherapy or as clozapine augmentation, include neurostimulatory methods (ECT, rTMS, tDCS), psychotherapy for specific symptoms (CBT), physical activity for negative symptoms, or more experimental (DBS, virtual reality). Disclosure of Interest None Declared
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Mohr, P. (2026). Evidence-based treatment for treatment resistant schizophrenia. European Psychiatry, 69(S1), S51. https://doi.org/10.1192/j.eurpsy.2026.10281
MLA 9
Mohr, Pavel. “Evidence-based treatment for treatment resistant schizophrenia.” European Psychiatry, vol. 69, no. S1, 2026, p. S51. https://doi.org/10.1192/j.eurpsy.2026.10281.
Chicago
Mohr, Pavel. 2026. “Evidence-based treatment for treatment resistant schizophrenia.” European Psychiatry 69 (S1): S51. https://doi.org/10.1192/j.eurpsy.2026.10281.
Harvard
Mohr, P. (2026) ‘Evidence-based treatment for treatment resistant schizophrenia’, European Psychiatry, 69(S1), p. S51. doi:10.1192/j.eurpsy.2026.10281.
IEEE
P. Mohr, “Evidence-based treatment for treatment resistant schizophrenia,” European Psychiatry, vol. 69, no. S1, p. S51, 2026, doi: 10.1192/j.eurpsy.2026.10281.
BibTeX
@article{mohr2026evidence,
title = {{Evidence-based treatment for treatment resistant schizophrenia}},
author = {Mohr, Pavel},
journal = {European Psychiatry},
year = {2026},
volume = {69},
number = {S1},
pages = {S51},
doi = {10.1192/j.eurpsy.2026.10281},
url = {https://doi.org/10.1192/j.eurpsy.2026.10281}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- treatment-resistant schizophrenia
- clozapine
- pseudoresistance
- electroconvulsive therapy
- memantine
- mirtazapine
- duloxetine
- aripiprazole
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Mohr, P. (2026). Evidence-based treatment for treatment resistant schizophrenia. European Psychiatry, 69(S1), S51. https://doi.org/10.1192/j.eurpsy.2026.10281
How many times has this paper been cited?
0 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at European Psychiatry: sign in and open the PDF from this page.
Who wrote this paper?
Pavel Mohr.
What is the DOI of this paper?
10.1192/j.eurpsy.2026.10281, permanently at https://doi.org/10.1192/j.eurpsy.2026.10281. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.